Cargando…

Plague vaccines: current developments and future perspectives

Despite many decades of intensive studies of Yersinia pestis, the causative agent of plague, there is no safe and efficient vaccine against this devastating disease. A recently developed F1/V subunit vaccine candidate, which relies mainly on humoral immunity, showed promising results in animal studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Feodorova, Valentina A, Motin, Vladimir L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630923/
https://www.ncbi.nlm.nih.gov/pubmed/26038406
http://dx.doi.org/10.1038/emi.2012.34
_version_ 1782266728150990848
author Feodorova, Valentina A
Motin, Vladimir L
author_facet Feodorova, Valentina A
Motin, Vladimir L
author_sort Feodorova, Valentina A
collection PubMed
description Despite many decades of intensive studies of Yersinia pestis, the causative agent of plague, there is no safe and efficient vaccine against this devastating disease. A recently developed F1/V subunit vaccine candidate, which relies mainly on humoral immunity, showed promising results in animal studies; however, its efficacy in humans still has to be carefully evaluated. In addition, those developing next-generation plague vaccines need to pay particular attention to the importance of eliciting cell-mediated immunity. In this review, we analyzed the current progress in developing subunit, DNA and live carrier platforms of delivery by bacterial and viral vectors, as well as approaches for controlled attenuation of virulent strains of Y. pestis.
format Online
Article
Text
id pubmed-3630923
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36309232013-05-13 Plague vaccines: current developments and future perspectives Feodorova, Valentina A Motin, Vladimir L Emerg Microbes Infect Review Despite many decades of intensive studies of Yersinia pestis, the causative agent of plague, there is no safe and efficient vaccine against this devastating disease. A recently developed F1/V subunit vaccine candidate, which relies mainly on humoral immunity, showed promising results in animal studies; however, its efficacy in humans still has to be carefully evaluated. In addition, those developing next-generation plague vaccines need to pay particular attention to the importance of eliciting cell-mediated immunity. In this review, we analyzed the current progress in developing subunit, DNA and live carrier platforms of delivery by bacterial and viral vectors, as well as approaches for controlled attenuation of virulent strains of Y. pestis. Nature Publishing Group 2012-11 2012-11-07 /pmc/articles/PMC3630923/ /pubmed/26038406 http://dx.doi.org/10.1038/emi.2012.34 Text en Copyright © 2012 Shanghai Shangyixun Cultural Communication Co., Ltd http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Review
Feodorova, Valentina A
Motin, Vladimir L
Plague vaccines: current developments and future perspectives
title Plague vaccines: current developments and future perspectives
title_full Plague vaccines: current developments and future perspectives
title_fullStr Plague vaccines: current developments and future perspectives
title_full_unstemmed Plague vaccines: current developments and future perspectives
title_short Plague vaccines: current developments and future perspectives
title_sort plague vaccines: current developments and future perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630923/
https://www.ncbi.nlm.nih.gov/pubmed/26038406
http://dx.doi.org/10.1038/emi.2012.34
work_keys_str_mv AT feodorovavalentinaa plaguevaccinescurrentdevelopmentsandfutureperspectives
AT motinvladimirl plaguevaccinescurrentdevelopmentsandfutureperspectives